SCHEMBL29802419

SCHEMBL29802419

O=C1NCC2c3ccccc3Oc3cccc1c32

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 9/20 0.40
PARP3 Q9Y6F1 1/20 0.40
NISCH Q9Y2I1 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
CDC7 O00311 1/20 0.36
ATM Q13315 1/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP19A1 P11511 1/20 0.35
CA12 O43570 1/20 0.34
CA9 Q16790 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30312068 1.00 PARP1 (0.40) PARP1PARP3NISCHMAOAMAOB
SCHEMBL217432 1.00 PARP1 (0.40) PARP1PARP3NISCHMAOAMAOB
SCHEMBL14336651 0.84 GAA (0.39) PARP1KMT2ACYP19A1
SCHEMBL14336465 0.80 PARP1 (0.34) PARP1PARP3
SCHEMBL14336724 0.80 PARP1 (0.33) PARP1CDC7
SCHEMBL29960421 0.75 HTR2A (0.55) PARP1PARP3MAOACA12CA9
SCHEMBL7142349 0.75 LMNA (0.39) PARP1NISCHMAOAMAOBATM
SCHEMBL14336530 0.74 HTT (0.44) MEN1LMNAKMT2A
SCHEMBL14336466 0.72 PHGDH (0.40) PARP1LMNAMAPTKMT2A
SCHEMBL7144469 0.72 NISCH (0.40) PARP1NISCHMAOAMAOBATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022204150-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS BLUE OAK PHARMACEUTICALS, INC. (US) 2022-09-29 WO disclosed
WO-2022190064-A1 METHODS FOR IDENTIFYING SUBJECTS WITH BETACORONAVIRUS INFECTIONS WHO ARE AT RISK OF ACUTE RESPIRATORY SYNDROME AND METHODS FOR THE TREATMENT OF SAME VEXO PHARMACEUTICALS DMCC (AE) 2022-09-15 WO disclosed